Search results for " inhalation"

showing 10 items of 231 documents

Anti-muscarinic drugs as preventive treatment of exercise-induced bronchoconstriction (EIB) in children and adults.

2020

Regular physical activity is strongly recommended to prevent chronic respiratory diseases, including asthma. On the other hand, vigorous physical training may trigger airway symptoms and bronchoconstriction. The transient airway narrowing occurring because of exercise is named exercise-induced bronchoconstriction (EIB). Despite management according to guidelines, a significant proportion of patients experiences uncontrolled EIB, which thus represents a relevant unmet medical need. In particular, although prevention and treatment of EIB are effectively based on the use of beta-2 bronchodilator drugs, high heterogeneity in individual responses has been reported. Furthermore, even though beta-…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classBronchoconstrictionMuscarinic Antagonists03 medical and health sciencesYoung Adult0302 clinical medicineBronchodilatorAdministration InhalationRespiratory HypersensitivityMedicineAdrenergic DrugsHumans030212 general & internal medicineIntensive care medicineAdverse effectChildAsthmabusiness.industrymedicine.diseaseResponse VariabilityExercise-induced bronchoconstrictionBronchodilator AgentsAnti-muscarinic030228 respiratory systemDelayed-Action PreparationsSettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREAnti muscarinicSystematic reviewBronchoconstrictionFemalemedicine.symptomAirwaybusinesshuman activitiesPhysical Conditioning HumanRespiratory medicine
researchProduct

A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.

2008

This dose-ranging study assessed the bronchodilator efficacy and tolerability of indacaterol, a novel once-daily inhaled beta2-agonist, in subjects clinically diagnosed with COPD. Comparative data with tiotropium were collected. In the double-blind, core period of the study, 635 subjects with COPD (prebronchodilator FEV(1)40% of predicted and > or =1.0L; FEV1/FVC <70%) were randomized to receive indacaterol 50, 100, 200 or 400microg or placebo via multi-dose dry powder inhaler, or indacaterol 400microg via single-dose dry powder inhaler, once daily for 7 days. After completing double-blind treatment and washout, a subset of subjects from each treatment group entered an open-label extension …

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyEfficacymedicine.drug_classScopolamine DerivativesQuinolonesFEV1/FVC ratioPulmonary Disease Chronic ObstructiveDouble-Blind MethodBronchodilatorForced Expiratory VolumeAdministration InhalationCOPDMedicineHumansTiotropium BromideIndacaterolAgedCOPDDose-Response Relationship Drugbusiness.industryTiotropiumTiotropium bromideMiddle AgedDose-ranging studymedicine.diseaseDry-powder inhalerrespiratory tract diseasesSurgeryBronchodilator AgentsTreatment OutcomeTolerabilityDoseAnesthesiaIndansIndacaterolFemaleSafetybusinessmedicine.drugRespiratory medicine
researchProduct

Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2-5.

2020

Tiotropium Respimat is an efficacious add-on to maintenance treatment in patients with symptomatic asthma. Currently, the Global Initiative for Asthma (GINA) strategy recommends tiotropium for patients at Steps 4–5. To assess the clinical benefits of tiotropium Respimat across asthma severities, GINA Steps 2–5, a post hoc analysis of five double-blind trials (12–48-weeks; patients aged 18–75 years) investigated the effect of tiotropium Respimat, 5 μg or 2.5 μg, versus placebo, on peak forced expiratory volume in 1 s (FEV1) within 3 h post-dose (FEV1(0–3h)) response, and Asthma Control Questionnaire-7 (ACQ-7) responder rate. GINA step grouping was based on patients’ background treatment regi…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyRespimatAdolescentINHALED CORTICOSTEROIDSPlaceboSALMETEROLDouble-Blind MethodADD-ONStatistical significanceInternal medicineAsthma controlPost-hoc analysisAdministration InhalationmedicineHumansPharmacology (medical)Tiotropium BromideCOMBINATIONDisease severityLungAsthmaAgedbusiness.industryTiotropiumBiochemistry (medical)IMPROVES LUNG-FUNCTIONOdds ratioMiddle Agedmedicine.diseaseGINAConfidence intervalLung functionAsthmarespiratory tract diseasesBronchodilator AgentsTreatment OutcomeSAFETYFemaleSalmeterolbusinessmedicine.drugSYMPTOMATIC ASTHMAPulmonary pharmacologytherapeutics
researchProduct

Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy.

2005

Objective: Pulmonary endarterectomy (PEA) is the standard therapy for patients with chronic thromboembolic pulmonary hypertension (CTEPH). In the immediate postoperative period, persistent pulmonary hypertension increases the risk of acute respiratory or right heart failure. In pulmonary arterial hypertension, prostanoid inhalation has been found to improve pulmonary hemodynamics, right ventricular function, gas exchange, and clinical outcome. We report the results of a double-blinded randomized trial with the aerosolized prostacyclin analogue iloprost in patients with residual pulmonary hypertension after PEA. Methods: Twenty-two patients (age, 55 � 13 years; 8 females; propofol- and sufen…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtymedicine.medical_treatmentHypertension PulmonaryPartial PressureVasodilator AgentsEndarterectomyPulmonary ArteryDouble-Blind MethodInternal medicineAdministration InhalationmedicineHumansIloprostProspective StudiesEndarterectomyAgedMechanical ventilationLungbusiness.industryPulmonary Gas ExchangeRespiratory diseaseHemodynamicsGeneral MedicineCarbon DioxideMiddle Agedmedicine.diseasePulmonary hypertensionOxygenmedicine.anatomical_structureTreatment OutcomeAnesthesiaCirculatory systemVascular resistanceCardiologySurgeryFemaleCardiology and Cardiovascular MedicinebusinessIloprostmedicine.drugEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
researchProduct

Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy.

2003

Abstract Background In primary pulmonary hypertension, aerosolized prostanoids selectively reduce pulmonary vascular resistance and improve right ventricular function. In this study, hemodynamic effects of inhaled iloprost, a stable prostacyclin analogue, were evaluated in patients with chronic thromboembolic pulmonary hypertension (CTEPH) before and early after pulmonary thromboendarterctomy (PTE). Methods Ten patients (mean age 49 years old [32 to 70 years old], New York Heart Association functional class III and IV) received a dose of 33 μg aerosolized iloprost immediately before surgery (T1), after intensive care unit admission (T2), and 12-hours postoperatively (T3). Effects on pulmona…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_treatmentHypertension PulmonaryVasodilator AgentsHemodynamicsEndarterectomymedicine.arteryAdministration InhalationPreoperative CaremedicineHumansIloprostPostoperative PeriodEndarterectomyAgedPulmonary thromboendarterectomybusiness.industryRespiratory diseaseMiddle Agedmedicine.diseasePulmonary hypertensionmedicine.anatomical_structureAnesthesiaPulmonary arteryChronic DiseaseVascular resistanceSurgeryFemaleCardiology and Cardiovascular MedicinebusinessPulmonary EmbolismIloprostmedicine.drugThe Annals of thoracic surgery
researchProduct

Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT)study follow-up

2019

Abstract Background Chronic obstructive pulmonary disease (COPD) is characterised by recurring exacerbations. We estimated the costs of healthcare resources for COPD management funded by the Italian National Healthcare Service (INHS) for one year. Methods We examined the demographic, clinical, and economic variables at enrolment and follow-up visits (at 6 and 12 months) of COPD patients participating in the SAT study and referred to 20 Italian pulmonary centres with different institutional characteristics. Costs were expressed in Euro (€) 2018. A random effects log-linear panel regression model was performed to predict the average cost per patient. Results Most of the centres were public in…

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtyCost-Benefit AnalysisSocio-culturaleMuscarinic AntagonistsPersonal SatisfactionSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineHealth careMedicineHumansCOPD management Econometric model Healthcare costs030212 general & internal medicineAdrenergic beta-2 Receptor AgonistsAverage costAgedAged 80 and overCOPDbiologyCOPD management; Econometric model; Healthcare costsbusiness.industryCOPD managementOxygen Inhalation TherapyRegression analysisHealth Care CostsLamaMiddle AgedHealthcare costsbiology.organism_classificationmedicine.diseaseRandom effects modelBronchodilator AgentsPatient Care ManagementRespiratory Function TestsEconometric model030228 respiratory systemItalyEmergency medicinePublic universityDisease ProgressionPatient ComplianceDrug Therapy CombinationbusinessPanel dataFollow-Up Studies
researchProduct

Revising old principles of inhaled treatment in new fixed combinations for asthma.

2015

The major influencing factors on persistent asthma control are the selected treatment(s), the drug delivery route and patient's adherence to therapy, together with the influence of lifestyle (i.e. sedentary habit), comorbid conditions and specific asthma phenotypes. Inhaled corticosteroids (ICS) in combination with a long-acting β2-agonist (LABA) are the gold standard for management of persistent asthma, with maximal local targeting and minimal systemic side effects. Several innovative inhaler devices have been developed for effective local drug administration and good patient compliance to therapy. Recently, a new ICS/LABA fixed combination, formulated with fluticasone propionate (FP) and …

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtyDoseAdolescentmedicine.drug_classSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionateFluticasone propionatelaw.inventionMedication AdherenceRandomized controlled triallawInternal medicineDrug CombinationFormoterol FumarateAdministration InhalationmedicineCorticosteroidAnti-Asthmatic AgentHumansPharmacology (medical)Anti-Asthmatic AgentsBronchodilator AgentAsthmabusiness.industryInhalerMedicine (all)Biochemistry (medical)medicine.diseaseAsthmaDiscontinuationInhaled treatmentBronchodilator AgentsDrug CombinationsAnesthesiaCorticosteroidFluticasoneFormoterol Fumaratebusinessmedicine.drugHumanPulmonary pharmacologytherapeutics
researchProduct

Does the frequency of switching inhalers represent a predictive factor of exacerbation in asthma?

2020

Objective: Management of asthma includes monitoring of inhaler technique and level of adherence to treatment. Both factors could be influenced by high frequency of switching inhaler devices. We explored whether switching inhalers is an independent predictive factor of exacerbations. Methods: Data were collected from 2015 to 2017 from the outpatient clinic of asthma at the University of Palermo, Italy. This observational study consisted of two phases: Phase 1 included subjects of at least three visits in the previous year who reported the frequency of inhalers switched; Phase 2 included subjects of at least two visits during the second year, and the rate of switches and exacerbations was rec…

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtyExacerbationSettore MED/10 - Malattie Dell'Apparato Respiratorioexacerbation: inhaler03 medical and health sciencesYoung Adult0302 clinical medicineAdrenal Cortex HormonesAdministration InhalationmedicineImmunology and AllergyHumans030212 general & internal medicineAnti-Asthmatic AgentsIntensive care medicinedeviceAsthmaAgedAged 80 and overbusiness.industryInhalerNebulizers and VaporizersMiddle Agedmedicine.diseaseAsthmaswitchPredictive factorHospitalization030228 respiratory systemPediatrics Perinatology and Child Healthbusiness
researchProduct

Prenatal tobacco smoke exposure increases hospitalizations for bronchiolitis in infants

2015

Background Tobacco smoke exposure (TSE) is a worldwide health problem and it is considered a risk factor for pregnant women’s and children’s health, particularly for respiratory morbidity during the first year of life. Few significant birth cohort studies on the effect of prenatal TSE via passive and active maternal smoking on the development of severe bronchiolitis in early childhood have been carried out worldwide. Methods From November 2009 to December 2012, newborns born at ≥33 weeks of gestational age (wGA) were recruited in a longitudinal multi-center cohort study in Italy to investigate the effects of prenatal and postnatal TSE, among other risk factors, on bronchiolitis hospitalizat…

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtyPediatricsTime FactorsTime FactorOffspringLongitudinal StudieRisk AssessmentTobacco smoke exposure Pregnancy Infant Bronchiolitis Hospitalization Risk factorBronchiolitis; Hospitalization; Infant; Pregnancy; Risk factor; Tobacco smoke exposure; Adult; Age Factors; Bronchiolitis; Female; Humans; Infant; Infant Newborn; Inhalation Exposure; Italy; Longitudinal Studies; Maternal Exposure; Pregnancy; Risk Assessment; Risk Factors; Smoking; Time Factors; Tobacco Smoke Pollution; Hospitalization; Prenatal Exposure Delayed Effects; Pulmonary and Respiratory MedicineRisk FactorsPregnancymedicineHumansAge FactorLongitudinal StudiesBronchiolitiRisk factorIntensive care medicineInhalation exposurePregnancyInhalation Exposurebusiness.industryResearchSmokingAge FactorsInfant NewbornGestational ageInfantNewbornmedicine.diseaseHospitalizationItalyBronchiolitisMaternal ExposureTobacco smoke exposurePrenatal Exposure Delayed EffectsBronchiolitisFemaleTobacco Smoke PollutionRisk factorRisk assessmentbusinessHumanCohort study
researchProduct

ERS clinical practice guidelines:high-flow nasal cannula in acute respiratory failure

2022

BackgroundHigh-flow nasal cannula (HFNC) has become a frequently used noninvasive form of respiratory support in acute settings; however, evidence supporting its use has only recently emerged. These guidelines provide evidence-based recommendations for the use of HFNC alongside other noninvasive forms of respiratory support in adults with acute respiratory failure (ARF).Materials and methodologyThe European Respiratory Society task force panel included expert clinicians and methodologists in pulmonology and intensive care medicine. The task force used the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methods to summarise evidence and develop clinical recommendat…

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtymedicine.medical_treatmentmedicine.disease_causeInternal medicineOxygen therapymedicineCannulaHumansAcute respiratory failureIntensive care medicineCOPDRespiratory Distress SyndromeNoninvasive Ventilationbusiness.industryOxygen Inhalation Therapychronic respiratory failure - COPD - noinvasive ventilationmedicine.diseaseClinical PracticeOxygenPulmonologyBreathingHigh flowbusinessRespiratory InsufficiencyNasal cannula
researchProduct